Julio Rosenstock
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1831133529
Payments from drug & device makers
Across 9,187 payments — averaging $2705.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$13.4M
- Novo Nordisk AS$4.9M
- Sanofi US Services Inc.$1.4M
- Boehringer Ingelheim$1.1M
- Pfizer$932K
- Novartis$806K
- plus $2.4M from 36 others
Across 137 payments — averaging $2401.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$200K
- Sanofi-aventis U.S. LLC$42K
- Bayer$37K
- Applied Therapeutics, Inc.$35K
- Novo Nordisk AS$13K
- Regeneron$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$24,855,856 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Dallas
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
- Michelle WelchShavano Park$17.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.